Literature DB >> 7338574

Comparative ototoxicity of bumetanide and furosemide when used in combination with kanamycin.

R E Brummett, T Bendrick, D Himes.   

Abstract

The ototoxicity of bumetanide and furosemide was compared in Topeka strain guinea pigs pretreated with kanamycin. The animals, anesthetized with pentobarbital, received a single dose of 400 mg/kg kanamycin subcutaneously and the diuretics via indwelling catheter in the jugular vein 2 hours later. Ototoxic drug effects were determined by measuring the electrophysiological responses of the cochlea to sound stimuli and by determining the presence or absence of cochlear sensory hair cells from the organ of Corti. Both bumetanide and furosemide produced permanent alteration of cochlear activity in the kanamycin-pretreated animals. The ototoxic effect of bumetanide is five times that of furosemide on a milligram-for-milligram basis. The ototoxic potential of bumetanide is one eighth that of furosemide when the doses are adjusted for diuretic potency difference between the two diuretics.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7338574     DOI: 10.1002/j.1552-4604.1981.tb05675.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  16 in total

Review 1.  Vancomycin- and erythromycin-induced hearing loss in humans.

Authors:  R E Brummett; K E Fox
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

Review 2.  Diuretics in pediatrics : current knowledge and future prospects.

Authors:  Maria M J van der Vorst; Joana E Kist; Albert J van der Heijden; Jacobus Burggraaf
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

Review 3.  Screening for chemicals that affect hair cell death and survival in the zebrafish lateral line.

Authors:  Henry Ou; Julian A Simon; Edwin W Rubel; David W Raible
Journal:  Hear Res       Date:  2012-01-31       Impact factor: 3.208

4.  Mycobacterium avium-M. intracellulare and Acquired Immunodeficiency Syndrome.

Authors:  E Wolinsky; C R Horsburgh; D L Cohn; R B Roberts; H Masur; R Miller; A Y Tsang; M D Iseman
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

Review 5.  Diuretics. Clinical pharmacology and therapeutic use (Part II).

Authors:  A Lant
Journal:  Drugs       Date:  1985-02       Impact factor: 9.546

6.  Supporting cell characteristics in long-deafened aged mouse ears.

Authors:  Elizabeth C Oesterle; Sean Campbell
Journal:  J Assoc Res Otolaryngol       Date:  2009-07-31

Review 7.  The altered pharmacokinetics and pharmacodynamics of drugs commonly used in critically ill patients.

Authors:  A Bodenham; M P Shelly; G R Park
Journal:  Clin Pharmacokinet       Date:  1988-06       Impact factor: 6.447

8.  Bumetanide hyperpolarizes madin-darby canine kidney cells and enhances cellular gentamicin uptake by elevating cytosolic Ca(2+) thus facilitating intermediate conductance Ca(2+)--activated potassium channels.

Authors:  Tian Wang; Yu-Qin Yang; Takatoshi Karasawa; Qi Wang; Amanda Phillips; Bing-Cai Guan; Ke-Tao Ma; Meiyan Jiang; Ding-Hua Xie; Peter S Steyger; Zhi-Gen Jiang
Journal:  Cell Biochem Biophys       Date:  2013-04       Impact factor: 2.194

9.  Potential drug interactions and chemotoxicity in older patients with cancer receiving chemotherapy.

Authors:  Mihaela A Popa; Kristie J Wallace; Antonella Brunello; Martine Extermann; Lodovico Balducci
Journal:  J Geriatr Oncol       Date:  2014-05-10       Impact factor: 3.599

Review 10.  Bumetanide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use.

Authors:  A Ward; R C Heel
Journal:  Drugs       Date:  1984-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.